(This was originally published on January 24, 2020.)

As pharmaceutical pipelines become tighter, more complex, and expensive, drug firms are taking a hard look at offering new delivery mechanisms and prepackaged drug/device kits. The FDA 510(k) Program, also referred to as premarket notification, is an FDA marketing clearance application and is the most common avenue of premarket submission for medical devices.

This article serves to provide you with a high-level understanding of the items required in 510(k) submissions and resources to help you during the process, including:

  • Device classifications
  • Substantial equivalence
  • Types of 510(k) submissions
  • What goes into a 510(k) submission
  • Researching other 510(k) submissions

[Related: Click here to view a sample 510(k) submission and see what one medical device firm included in its 510(k) submission.]

510k sample opt-in

Why is it called a 510(k)?

The name 510(k) refers to the 510(k) section of the Federal Food, Drug and Cosmetic Act. For an outline of 510(k) submission requirements, review 21 CFR 807 subpart E.

Device Classifications

FDA regulates medical devices based on risk. There are three classes of medical devices:

  • Class I:
    • Low-risk devices
    • Subject to general controls
    • Most are exempt from premarket notification process
  • Class II:
    • Moderate-risk devices
    • Subject to general and special controls
    • Most require premarket notification
  • Class III:
    • High-risk devices
    • Subject to general controls and premarket approval

Most product codes are found on all 510(k) clearance letters. These can be useful when searching for relevant products that have similar codes (keep reading to learn more about searching 510(k) clearance letters).

When is a 510(k) required?

510(k) is required under the following conditions:

  • Introducing a new device to the market for the first time.
  • Changing the indications for use of a previously cleared device.
  • Making significant modifications to a previously cleared device.

What Are the Types of Submissions?

There are three types of 510(k) submissions: traditional, abbreviated, and special. With all three types, the required elements of 21 CFR 807.87 must be submitted. These are administrative requirements including items like business name, etc.

Traditional submissions can be used under any circumstance. These submissions rely on the demonstration of Substantial Equivalence, which we will discuss later in this article.

Abbreviated submissions can only be used if certain criteria are met. These submissions rely on the use of guidance documents, recognized standards, special controls, etc.

Special submissions are used when you are making modifications to your own product that is a legally marketed device. Note that modifications cannot affect the intended use of the fundamental technology of the device because that data is not typically submitted with a 510(k).

FDA has provided helpful checklists to use when preparing your 510(k).

What Should Be Submitted in Your 510(k)?

The following items are all required in your premarket notification:

  • Table of contents with appropriate paging.
  • Administrative requirements, certain forms and cover letters.
  • Intended use and indication for use, including indication of prescription use or OTC.
  • 510(k) summary.
  • Detailed device description. This can include figures, diagrams, materials (including patient-contacting materials), energy sources, technological features, etc. Note: it would be prudent to include as many visuals as possible.
  • Detailed discussion of Substantial Equivalence based on a predicate device (see section below for more information on Substantial Equivalence and predicate devices).
  • Proposed labeling for your device.
    • The proposed labeling should comply with 21 CFR 801. Copies of all labeling are recommended, including package insert, service manuals, instructions for use, advertising and promotional materials, etc. Copies of your predicate device’s labeling is recommended but not required.
  • Performance testing (bench, animal, or clinical) or comparative testing. Device-specific guidance documents may provide recommendations on appropriate performance testing. Testing should include test methods, acceptance criteria, and test results.

Substantial Equivalence and Predicate Devices

A 510(k) is based on the determination of Substantial Equivalence; it is the entire point of a 510(k). 510(k) submissions can be hundreds of pages long, if necessary, to demonstrate Substantial Equivalence. A successful 510(k) will result in FDA clearance. Note that 510(k) clearance does not indicate FDA approval – it is simply FDA cleared.

Substantial Equivalence requires the use of a predicate (comparable) device to demonstrate that the device in review has the same intended use and technological characteristics. Predicate devices are legally marketed devices that have been, typically, cleared through the 510(k) process already. Note that differences in technological characteristics may be allowed if these characteristics do not indicate or raise questions of safety and effectiveness.

Premarket reviewers consult a 510(k) decision-making flowchart when assessing Substantial Equivalence. Those producing a 510(k) submission would be wise to review the chart and make sure they address every decision point (link below).

The following documents regarding Substantial Equivalence and predicate devices should be read:

Here are a few additional notes on the subject:

  • Multiple predicate devices are only acceptable under certain circumstances. Refer to the 510(k) final guidance to know when this is appropriate. Also, split predicates are inconsistent with the 510(k) regulatory standard.
  • Reference Devices may also be used to support scientific methodology or standard reference values. Note that these are not predicate devices.
  • If after due diligence no identifiable predicate device is known, you may want to consider a de novo.

Researching FDA Regulation, Summaries, and Previous 510(k) Submissions

Researching FDA regulation of medical devices begins at https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/510k-clearances, where FDA explains the medical device premarket notification submission process and offers links to listings of devices cleared for market and, sometimes, a sponsor-prepared device summary as specified in 21 CFR 807.92(c).

Viewing a sample 510(k) that has already been submitted can also be valuable. Redica Systems offers a free sample 510(k) that can be downloaded here. This sample 510(k) includes FDA correspondence, amendments, and reviewer information. Medical device manufacturers can use this sample 510(k) as a guide for their next submission.

For Questions

FDA recognizes that preparing a 510(k) can be complex and confusing. To that end, the Center for Devices and Radiological Health (CDRH) has established the Division of Industry and Consumer Education (DICE), which offers help in resolving medical device questions and generally responds to questions within two working days. Contact information is available at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice.

The same page also offers a link to “Device Advice” which addresses the most commonly asked questions about device definition, how to study and market a device, user fees, device registration and listing, and online training for the medical device industry.

510k sample opt-in

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.